Sitagliptin and exenatide associated with an increased risk of acute pancreatitis
Source: JAMA Internal Medicine
Area: News
According to a study published in JAMA Internal Medicine, treatment of type 2 diabetes mellitus with the glucagon-like peptide (GLP)-1-based therapies sitagliptin and exenatide was associated with increased odds of hospitalisation for acute pancreatitis.
A large administrative database in the United States was used to collect data for the population-based case-control study - adults with type 2 diabetes mellitus aged 18 to 64 years were identified and 1269 hospitalised cases with acute pancreatitis using a validated algorithm and 1269 control subjects matched for age category, sex, enrollment pattern, and diabetes complications were determined. The mean age of included individuals was 52 years, and 57.45% were male. The primary outcome measure was hospitalisation for acute pancreatitis. The following results were reported:
. After adjusting for available confounders and metformin hydrochloride use, current use of GLP-1-based therapies within ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news
More News: Byetta | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Fortamet | Internal Medicine | Janumet | Januvia | Metformin | Pancreatitis | Study